**IN THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A sodium channel blocker represented by the ~~general~~ structure:




I

wherein R is selected from the group consisting of ~~$C_1$-$C_{12}$ alkyl~~, $C_1$ alkyl, $C_3$-$C_6$ alky, $C_8$-$C_{12}$ alkyl, $C_2$-$C_9$ alkenyl, $C_2$-$C_9$ alkynyl, -$(CH_2)_mCOOH$, -$(CH_2)_mNH_2$, -$(CH_2)_mCONH_2$, -$(CH_2)_nC_3$-$C_6$ cycloalkyl, -$(CH_2)_n$aryl, -$(CH_2)_n$~~substituted~~ aryl, -$(CH_2)_pNCH_3(CH_2)_p$~~substituted~~ aryl and -$(CH_2)_n$~~substituted~~ heterocyclic, wherein m is an integer ranging from 3-8, n is an integer ranging from 0-4 and p is an integer ranging from 1-4;

$R_2$ is selected from the group consisting of -$(CH_2)_nCOOH$, -$(CH_2)_nNH_2$, and -$(CH_2)_nCONHR_{10}$; with the proviso that when $R_2$ is -$(CH_2)_nCONHR_{10}$, n is 3 or 4;

$R_3$ is selected from the group consisting of hydroxy, amino, $C_1$-$C_4$ alkoxy, -$CH_2OH$ and -$CONH_2$, or $R_2$ and $R_3$ taken together with the atoms to which they are attached form ~~an optionally substituted~~ a heterocyclic ring;

$R_4$ and $R_5$ are independently selected from the group consisting of H, halo, $C_1$-$C_4$ alkyl, $C_2$-$C_4$ alkenyl, $C_2$-$C_4$ alkynyl, and $C_1$-$C_4$ alkoxy; and

$R_6$ is selected from the group consisting of H, $C_1$-$C_8$ alkyl,




and




,

wherein $R_7$ and $R_8$ are independently selected from the group consisting of H, $C_1$-$C_4$ alkyl, $C_2$-$C_4$ alkenyl and $C_2$-$C_4$ alkynyl, and $R_9$ is H, or $R_8$ and $R_9$ taken together with the atoms to which

they are attached form ~~an optionally substituted~~ a heterocyclic ring, and $R_{10}$ is selected from the group consisting of H, benzyl and $C_1$-$C_4$ alkyl, with the proviso that when $R_2$ and $R_3$ taken together form a heterocyclic ring, R is not -$(CH_2)_n$aryl.

2. (Original) The compound of claim 1, wherein $R_2$ is -$(CH_2)_nCONH_2$; and $R_3$ is hydroxyl.

3. (Withdrawn) The compound of claim 1, wherein $R_2$ and $R_3$ taken together with the atoms to which they are attached form a heterocyclic ring having the structure:



,

wherein X is selected from the group consisting of -$CHR_{12}$-, -O- and -$NR_{12}$-, wherein $R_{11}$ and $R_{12}$ are independently selected from the group consisting of H, benzyl and $C_1$-$C_4$ alkyl.

4. (Currently Amended) The compound of claim 2 ~~or 3~~ wherein R is selected from the group consisting of ~~$C_1$-$C_{12}$ alkyl~~, $C_1$ alkyl, $C_3$-$C_6$ alky, $C_8$-$C_{12}$ alkyl, $C_2$-$C_8$ alkenyl and $C_2$-$C_8$ alkynyl.

5. (Currently Amended) The compound of claim 2 ~~or 3~~ wherein $R_4$ and $R_5$ are independently selected from the group consisting of H, halo and $C_1$-$C_4$ alkyl; and

$R_6$ is selected from the group consisting of H,



and



wherein n is an integer ranging from 0-2.

6. (Original) The compound of claim 5 wherein $R_4$ and $R_6$ are both H, and $R_5$ is Cl or F.

7. (Original) The compound of claim 5 wherein $R_4$ and $R_5$ are both H, and $R_6$ is



wherein n is an integer ranging from 0-2.

8. (Original) The compound of claim 5 wherein $R_4$ and $R_5$ are both $C_1$-$C_4$ alkyl, and $R_6$ is



wherein n is an integer ranging from 0-2.

9. (Currently Amended) The compound of claim 2 ~~or 3~~ wherein R is



or



;

$R_4$ and $R_5$ are independently selected from the group consisting of H, halo and $C_1$-$C_4$ alkoxy; and

$R_6$ is H.

10. (Currently Amended) A pharmaceutical composition comprising a compound represented by the ~~general~~ formula:




or




wherein R is selected from the group consisting of ~~$C_1$-$C_{12}$ alkyl~~, $C_1$ alkyl, $C_3$-$C_6$ alky, $C_8$-$C_{12}$ alkyl, $C_2$-$C_8$ alkenyl, $C_2$-$C_8$ alkynyl, -$(CH_2)_nC_3$-$C_6$ cycloalkyl,




and




wherein n is an integer ranging from 0-4;

$R_2$ is H or $C_1$-$C_4$ alkyl;

$R_4$ and $R_5$ are independently selected from the group consisting of H, halo, $C_1$-$C_4$ alkyl, $C_2$-$C_4$ alkenyl, $C_2$-$C_4$ alkynyl, -$COR_{11}$ and ($C_1$-$C_4$) alkoxy; and

$R_6$ is selected from the group consisting of H, halo,




,




and




wherein $R_{11}$ is selected from the group consisting of H, $C_1$-$C_4$ alkyl, $NH_2$ and OH; and

a pharmaceutically acceptable carrier.

11. (Original) The composition of claim 10 further comprising an anti-tumor agent.

12. (Original) The composition of claim 11, wherein the anti-tumor agent is a chemotherapeutic.

13. (Currently Amended) The composition of claim 10, wherein R is selected from the group consisting of ~~$C_1$-$C_{12}$ alkyl~~, $C_1$ alkyl, $C_3$-$C_6$ alky, and $C_8$-$C_{12}$ alkyl;

$R_4$ and $R_5$ are independently selected from the group consisting of H, halo and $C_1$-$C_4$ alkyl; and

$R_6$ is selected from the group consisting of H,




wherein n is an integer ranging from 0-4.

14. (Currently Amended) A method of specifically inhibiting voltage-gated sodium channels, said method comprising the step of contacting said sodium channel with a compound represented by the ~~general~~ structure:




wherein R is selected from the group consisting of ~~$C_1$-$C_{12}$ alkyl~~, $C_1$ alkyl, $C_3$-$C_6$ alky, $C_8$-$C_{12}$ alkyl, $C_2$-$C_8$ alkenyl, $C_2$-$C_8$ alkynyl, -$(CH_2)_nC_3$-$C_6$ cycloalkyl,




and




$R_4$ and $R_5$ are independently selected from the group consisting of H, halo, $C_1$-$C_4$ alkyl, $C_2$-$C_4$ alkenyl, $C_2$-$C_4$ alkynyl, -$COR_{11}$ and ($C_1$-$C_4$) alkoxy; and

$R_6$ is selected from the group consisting of H, halo,




,




and




wherein $R_{11}$ is selected from the group consisting of H, $C_1$-$C_4$ alkyl, $NH_2$ and OH, and n is an integer ranging from 0-4.

15. (Currently Amended) The method of claim 14 wherein R is selected from the group consisting of ~~$C_1$-$C_{12}$ alkyl~~, $C_1$ alkyl, $C_3$-$C_6$ alky, and $C_8$-$C_{12}$ alkyl;

$R_4$ and $R_5$ are independently selected from the group consisting of H, halo and $C_1$-$C_4$ alkyl; and

$R_6$ is selected from the group consisting of H,




,




and




wherein n is an integer ranging from 0-4.

16. (Withdrawn) A method for treating a neoplastic disease, said method comprising the step of administering to a patient in need thereof a composition comprising a compound represented by the general structure:




or




wherein R is selected from the group consisting of $C_1$-$C_{12}$ alkyl, $C_2$-$C_8$ alkenyl, $C_2$-$C_8$ alkynyl, -$(CH_2)_nC_3$-$C_6$ cycloalkyl,




and




wherein n is an integer ranging from 0-4;

$R_4$ and $R_5$ are independently selected from the group consisting of H, halo, $C_1$-$C_4$ alkyl, $C_2$-$C_4$ alkenyl, $C_2$-$C_4$ alkynyl, -$COR_{11}$ and ($C_1$-$C_4$) alkoxy; and

$R_6$ is selected from the group consisting of H, halo,




,




and



wherein $R_{11}$ is selected from the group consisting of H, $C_1$-$C_4$ alkyl, $NH_2$ and OH.

17. (Withdrawn) The method of claim 16 wherein R is selected from the group consisting of $C_1$-$C_{12}$ alkyl;

$R_4$ and $R_5$ are independently selected from the group consisting of H, halo and $C_1$-$C_4$ alkyl; and

$R_6$ is selected from the group consisting of H,




,




and




wherein n is an integer ranging from 0-4.

18. (Withdrawn) The method of claim 17 wherein $R_4$ and $R_5$ are independently selected from the group consisting of H and halo; and $R_6$ is H.

19. (Currently Amended) A sodium channel blocker represented by the ~~general~~ structure




or




wherein $R_4$ and $R_5$ are independently selected from the group consisting of H, halo and $C_1$-$C_4$ alkyl;

$R_6$ is selected from the group consisting of H,




and




wherein n is an integer ranging from 0-4 and

$R_{14}$ and $R_{15}$ are independently selected from the group consisting of H and halo~~, or $R_{14}$ and $R_{15}$ taken together with the atoms to which they are attached form an optionally substituted $C_5$-$C_6$ aryl~~.

20. (Canceled)